Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk (NYSE:NVO) and maintained a $160 price target.
June 17, 2024 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk and maintained a $160 price target, indicating continued confidence in the company's performance.
The reiteration of an Overweight rating and the maintenance of a $160 price target by a reputable analyst suggests positive sentiment and confidence in Novo Nordisk's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100